|
1
|
World Health Organization. Breast cancer:
prevention and control. www.who.int/cancer/detection/breastcancer/en/https://www.who.int/cancer/detection/breastcancer/en/.
Accessed Jan 6, 2013
|
|
2
|
World health statistics 2008: Part 1: Ten
highlights in health statistics. http://www.who.int/whosis/whostat/EN_WHS08_Part1.pdf.
Accessed Jan 6, 2013
|
|
3
|
The global burden of disease: 2004 update.
www.who.int/healthinfo/global_burden_disease/2004_report_update/en/https://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/.
Accessed Jan 6, 2013
|
|
4
|
Guo H, Ming J, Liu C, et al: A common
polymorphism near the ESR1 gene is associated with risk of breast
cancer: evidence from a case-control study and a meta-analysis.
PLoS One. 7:e524452012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li LW and Xu L: Menopausal status modifies
breast cancer risk associated with ESR1 PvuII and
XbaI polymorphisms in Asian women: a HuGE review and
meta-analysis. Asian Pac J Cancer Prev. 13:5105–5111. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu L and Chen J: Association of MTHFR
Ala222Val (rs1801133) polymorphism and breast cancer
susceptibility: An update meta-analysis based on 51 research
studies. Diagn Pathol. 7:1712012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wei G, Wang Y, Zhang P, Lu J and Mao JH:
Evaluating the prognostic significance of FBXW7 expression level in
human breast cancer by a meta-analysis of transcriptional profiles.
J Cancer Sci Ther. 4:299–305. 2012.PubMed/NCBI
|
|
8
|
Mao Q, Gao L, Wang H, Wang Q and Zhang T:
The alcohol dehydrogenase 1C(rs698) genotype and breast cancer: A
meta-analysis. Asia Pac J Public Health. May 31–2012.(Epub ahead of
print).
|
|
9
|
Wu MH, Chu CH, Chou YC, Chou WY, Yang T,
Hsu GC, Yu CP, Yu JC and Sun CA: Joint effect of peroxisome
proliferator-activated receptor γ genetic polymorphisms and
estrogen-related risk factors on breast cancer risk: results from a
case-control study in Taiwan. Breast Cancer Res Treat. 127:777–784.
2011.
|
|
10
|
Cho MC, Lee K, Paik SG and Yoon DY:
Peroxisome proliferators-activated receptor (PPAR) modulators and
metabolic disorders. PPAR Res. 2008:6791372008.PubMed/NCBI
|
|
11
|
Memisoglu A, Hankinson SE, Manson JE,
Colditz GA and Hunter DJ: Lack of association of the codon 12
polymorphism of the peroxisome proliferator-activated receptor
gamma gene with breast cancer and body mass. Pharmacogenetics.
12:597–603. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dallongeville J, Iribarren C, Ferrières J,
et al: Peroxisome proliferator-activated receptor gamma
polymorphisms and coronary heart disease. PPAR Res.
2009:5437462009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He W: PPARγ2 polymorphism and human
health. PPAR Res. 2009:8495382009.
|
|
14
|
Spiegelman BM: PPAR-gamma: adipogenic
regulator and thiazolidinedione receptor. Diabetes. 47:507–514.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ho JS, Germer S, Tam CH, et al:
Association of the PPARG Pro12Ala polymorphism with type 2 diabetes
and incident coronary heart disease in a Hong Kong Chinese
population. Diabetes Res Clin Pract. 97:483–491. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Prakash J, Srivastava N, Awasthi S, et al:
Association of PPAR-γ gene polymorphisms with obesity and
obesity-associated phenotypes in North Indian population. Am J Hum
Biol. 24:454–459. 2012.
|
|
17
|
Alsaleh A, Frost GS, Griffin BA, et al;
RISCK Study Investigators. PPARγ2 gene Pro12Ala and PPARα gene
Leu162Val single nucleotide polymorphisms interact with dietary
intake of fat in determination of plasma lipid concentrations. J
Nutrigenet Nutrigenomics. 4:354–366. 2011.
|
|
18
|
Poliska S, Penyige A, Lakatos PL, et al;
Hungarian IBD Study Group. Association of peroxisome
proliferator-activated receptor gamma polymorphisms with
inflammatory bowel disease in a Hungarian cohort. Inflamm Bowel
Dis. 18:472–479. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Justenhoven C, Hamann U, Schubert F, et
al: Breast cancer: a candidate gene approach across the estrogen
metabolic pathway. Breast Cancer Res Treat. 108:137–149. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, McCullough ML, Stevens VL, et al:
Nested case-control study of energy regulation candidate gene
single nucleotide polymorphisms and breast cancer. Anticancer Res.
27:589–593. 2007.PubMed/NCBI
|
|
21
|
Petersen RK, Larsen SB, Jensen DM, et al:
PPARgamma-PGC-1alpha activity is determinant of alcohol related
breast cancer. Cancer Lett. 315:59–68. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim KZ, Shin A, Lee YS, Kim SY, Kim Y and
Lee ES: Polymorphisms in adiposity-related genes are associated
with age at menarche and menopause in breast cancer patients and
healthy women. Hum Reprod. 27:2193–2200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wells GA, Shea B, O’Connell D, et al: The
Newcastle-Ottawa Scale (NOS) for assessing the quality of
nonrandomised studies in meta-analyses. Available from: URL:
www.ohri.ca/programs/clinical_epidemiology/oxford.asphttps://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
Accessed Nov 26, 2011
|
|
24
|
Wirtenberger M, Tchatchou S, Hemminki K,
et al: Associations of genetic variants in the estrogen receptor
coactivators PPARGC1A, PPARGC1B and EP300 with familial breast
cancer. Carcinogenesis. 27:2201–2208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Y, Li Y, Wedrén S, et al: Genetic
variation of ESR1 and its co-activator PPARGC1B is synergistic in
augmenting the risk of estrogen receptor-positive breast cancer.
Breast Cancer Res. 13:R102011. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Paynter RA, Hankinson SE, Colditz GA,
Hunter DJ and De Vivo I: No evidence of a role for PPARgamma
Pro12Ala polymorphism in endometrial cancer susceptibility.
Pharmacogenetics. 14:851–856. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Posch MG, Zang C, Mueller W, Lass U, von
Deimling A and Elstner E: Somatic mutations in peroxisome
proliferator-activated receptor-gamma are rare events in human
cancer cells. Med Sci Monit. 10:BR250–BR254. 2004.PubMed/NCBI
|
|
28
|
Ondrey F: Peroxisome
proliferator-activated receptor gamma pathway targeting in
carcinogenesis: implications for chemoprevention. Clin Cancer Res.
15:2–8. 2009. View Article : Google Scholar
|
|
29
|
Gallicchio L, McSorley MA, Newschaffer CJ,
et al: Body mass, polymorphisms in obesity-related genes, and the
risk of developing breast cancer among women with benign breast
disease. Cancer Detect Prev. 31:95–101. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vogel U, Christensen J, Nexø BA, Wallin H,
Friis S and Tjønneland A: Peroxisome profilerator-activated
[corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with
alcohol intake and NSAID use, in relation to risk of breast cancer
in a prospective study of Danes. Carcinogenesis. 28:427–434.
2007.
|
|
31
|
Lee E, Hsu C, Van den Berg D, et al:
Genetic variation in peroxisome proliferator-activated receptor
gamma, soy, and mammographic density in Singapore Chinese women.
Cancer Epidemiol Biomarkers Prev. 21:635–644. 2012. View Article : Google Scholar : PubMed/NCBI
|
